Company intelligence / Profile preview

Nanjing Zaiming Pharmaceutical

Nanjing, Jiangsu, Chinasimcere.com ↗

Ownership: Private
Development stage: Commercial

Overview

Simcere Zaiming focuses on innovative oncology therapeutics with a pipeline of 13 innovative drug projects, one of which (SIM0508) recently received clinical trial approval for solid tumors. SIM0500, a trispecific antibody, is in Phase 1 trials for multiple myeloma, and the company has products in advanced development for lung cancer, with key collaborations accelerating its clinical programs[2][4][6][8].

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyTrispecific antibody
Industry: Biotech

Drug pipeline

5 assets

SIM0518

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

AbbVieTargetRx

Beyond the preview

Go deeper on Nanjing Zaiming Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Zaiming Pharmaceutical.

Explore the full profile